- Home
- FBGL vs APRE Comparison
FBGL vs APRE Comparison
Compare FBGL & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBGL
- APRE
- Stock Information
- Founded
- FBGL 1996
- APRE 2006
- Country
- FBGL Singapore
- APRE United States
- Employees
- FBGL N/A
- APRE 8
- Industry
- FBGL Miscellaneous manufacturing industries
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FBGL Consumer Discretionary
- APRE Health Care
- Exchange
- FBGL Nasdaq
- APRE Nasdaq
- Market Cap
- FBGL 12.4M
- APRE 8.4M
- IPO Year
- FBGL 2025
- APRE 2019
- Fundamental
- Price
- FBGL $0.67
- APRE $1.55
- Analyst Decision
- FBGL
- APRE Strong Buy
- Analyst Count
- FBGL 0
- APRE 2
- Target Price
- FBGL N/A
- APRE $15.50
- AVG Volume (30 Days)
- FBGL 407.7K
- APRE 29.2K
- Earning Date
- FBGL 01-01-0001
- APRE 05-13-2025
- Dividend Yield
- FBGL N/A
- APRE N/A
- EPS Growth
- FBGL N/A
- APRE N/A
- EPS
- FBGL 0.04
- APRE N/A
- Revenue
- FBGL $15,607,369.00
- APRE $1,502,581.00
- Revenue This Year
- FBGL N/A
- APRE N/A
- Revenue Next Year
- FBGL N/A
- APRE N/A
- P/E Ratio
- FBGL $16.99
- APRE N/A
- Revenue Growth
- FBGL 25.78
- APRE 157.63
- 52 Week Low
- FBGL $0.44
- APRE $1.41
- 52 Week High
- FBGL $5.45
- APRE $5.90
- Technical
- Relative Strength Index (RSI)
- FBGL N/A
- APRE 31.36
- Support Level
- FBGL N/A
- APRE $1.41
- Resistance Level
- FBGL N/A
- APRE $1.59
- Average True Range (ATR)
- FBGL 0.00
- APRE 0.10
- MACD
- FBGL 0.00
- APRE 0.03
- Stochastic Oscillator
- FBGL 0.00
- APRE 31.26
About FBGL FBS Global Limited Ordinary Shares
FBS Global Ltd is a green building contractor and an established interior fit-out specialist in institutional, residential, commercial and industrial building projects. As a green contractor focused on environmentally sound practices, It aims to bid tenders for green building projects, use green construction methods and green materials for construction projects, including design, supply and installation of ceilings, partitions, timber deck, carpet, lead lining, acoustic wall paneling, built-in furniture as well as mechanical and electrical services of a building. The company's revenue is derived mainly from the construction contracts, sales of construction materials, and rendering of services.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.